CNBC's The China Connection newsletter: 'Spider-Man' and 'The Odyssey' come courting the massive filmgoer market

“Spider-Man: Brand New Day” has already entered China’s top 10 box office rankings this year, while “The Odyssey” has made $7M in two weekends ahead of its Aug. 14 release—evidence Hollywood can still win with Beijing’s tightly controlled market. However, overall China box office is down 40% in the first half of the year, and engagement is happening alongside policy risk: Beijing has tightened U.S.-linked export controls and new offshore trust tax rules impose 20% tax events on transfers since 2023 (back taxes due by Oct. 22). Separate data points also flag macro sensitivity, with China’s crude oil imports up to a three-month high in July as Strait of Hormuz tensions eased.

Analysis

IMAX is the only clean near-term expression because the marginal dollar of improvement in China is flowing to premium formats, not the broad exhibition market. In a low-fill-rate environment, incremental attendance can leverage into estimates faster than the headline market recovery implies, and that creates a tradable setup even if the overall China box office remains weak. The second-order winner is any operator that can monetize scarcity and eventize content; the losers are standard-screen theaters and studios relying on volume rather than pricing power.

The contrarian view is that this is a localization trade, not a secular China reacceleration. Demand is fragmenting toward local IP, short-form video, and immersive venues, so Hollywood titles may continue to produce spikes without changing the underlying trajectory of consumer spend. That means the opportunity is strongest over the next 1-3 months around slate-driven sentiment, but the 6-18 month durability is much less certain unless admissions and pricing stay elevated after the current release window.

BABA’s distribution optionality is real but too small to matter unless it can prove repeatable cross-border monetization; AAPL’s Vision Pro/VR angle is even further out and should be treated as a watch item. NFLX is a structural attention-economy loser in theory, but the China linkage is too indirect to justify a standalone short here. The key falsifier is simple: if post-release China admissions fade back quickly or IMAX fails to guide up on the next call, the trade should be cut.

Key Decisions for Investors

• Long IMAX into the next 2-4 weeks on China premium-screen utilization; use the Aug. 14 release window as the catalyst. Falsify if post-release admissions flatten or management does not confirm stronger Q3 demand.
• Use IMAX call spreads for the 1-3 month slate cycle instead of outright calls; the thesis is sentiment and estimate revision upside, not a durable structural re-rating.
• No standalone trade in BABA or AAPL yet; keep both on watch. Revisit BABA only if Damai shows measurable monetization over 1-2 quarters, and AAPL only if China VR/content partnerships become visible enough to matter in 12-24 months.
• Do not short NFLX on this note alone. If used at all, make it a small hedge inside a broader media basket, because the China-related signal is too indirect for high-conviction positioning.